Effects of bright light treatment on psychomotor speed in athletes.
Mikko P Tulppo, Heidi Jurvelin, Eka Roivainen...
https://pubmed.ncbi.nlm.nih.gov/24860513/Actively Recruiting
Led by Weill Medical College of Cornell University · Updated on 2026-09-23
12
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating whether bright light therapy can help synchronize the natural sleep-wake cycles circadian rhythms of patients with melanoma or non-small cell lung cancer NSCLC receiving first-line immune checkpoint blockade ICB therapy. This pilot study focuses on testing the feasibility and safety of delivering bright light therapy through the Circadian OS iPad application before starting ICB treatment. The goal is to see if timing ICB therapy with synchronized circadian rhythms improves clinical outcomes, as disrupted rhythms may reduce immunotherapy response. Participants will receive 60 minutes of daily bright light therapy via the Circadian OS iPad app for at least seven days before beginning their planned ICB regimens, which may include anti-PD-1, anti-CTLA-4, or combinations with chemotherapy. This single-arm study monitors adherence to the therapy and its tolerability, aiming to entrain patients circadian rhythms to optimize immune function at the time of immunotherapy. During the study, researchers will track how many participants complete at least 70% of the bright light therapy sessions over a minimum of seven consecutive days before starting ICB treatment. They will also monitor adverse events related to the therapy up to the first ICB dose. Participants need reliable internet access to use the app, and the study duration before ICB initiation is expected to be about one to three weeks. The trial is sponsored by Weill Medical College of Cornell University and will run until December 2027.
CONDITIONS
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
J
June Greenberg, BSN, RN, OCN, CCRP, CCRC
D
Daniella Topol, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Weill Medical College of Cornell University
Lead Sponsor
Circadian OS, Inc
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Bright Light Therapy (Circadian OS App) Added Before First-Line ICB | Current Care Without Circadian-Targeted Intervention |
|---|---|---|
| What it is | Bright Light Therapy involves daily 60-minute light exposure using the Circadian OS iPad app for at least 7 days before starting immune checkpoint blockade, aiming to entrain circadian rhythms. | Conventional supportive care prior to first-line ICB does not include targeted circadian rhythm interventions. Typical preparation involves routine clinical assessment and symptom management. |
| Role in the trial | All participants receive BLT as an adjunct before first-line ICB; there is no randomized comparator arm. | BLT is not routinely used in standard supportive care for melanoma or NSCLC. Usual care does not include circadian-targeted light therapy. |
| Primary use or goal | The goal is to enhance circadian rhythm stability and amplitude before immunotherapy, with the hypothesis that this may optimize immune response to ICB. | Routine care aims to assess fitness for ICB and manage symptoms; no interventions for circadian rhythm are standardly included. |
| How it is given or performed | Participants use the Circadian OS iPad app for 60 minutes daily in the week leading up to ICB initiation. Adherence is monitored over at least 7 days. | No formal circadian-targeted therapy is given. Patients may participate in general supportive care, including symptom management and education, as per conventional practice. |
| Evidence status | BLT is supported by evidence in cancer patients for improving sleep quality and reducing fatigue, though its effect on immunotherapy outcomes is not yet established in melanoma or NSCLC. | Conventional supportive care has not demonstrated effects on circadian rhythm or melatonin entrainment, and does not impact immunotherapy response through such mechanisms. |
| Important limitations | The trial is single-arm and small, so it cannot compare BLT directly with routine care outcomes or address long-term effects. Evidence on BLT improving immunotherapy response remains limited to early-phase investigation. | Standard supportive care does not address circadian rhythm disruptions, which are prevalent in advanced cancer. There is a lack of routinely implemented interventions targeting circadian rhythm or melatonin suppression. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - At least 7 days
Participants use the Circadian OS iPad application to receive 60 minutes of bright light therapy each morning for at least 7 days before starting immune checkpoint blockade treatment.
Daily sessions at home using the app
Duration - Varies per treatment plan
Participants begin their planned cancer immunotherapy regimen with immune checkpoint blockade drugs alone or combined with chemotherapy.
As per clinical schedule
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Mikko P Tulppo, Heidi Jurvelin, Eka Roivainen...
https://pubmed.ncbi.nlm.nih.gov/24860513/Henri Comtet, Pierre A Geoffroy, Mio Kobayashi Frisk...
https://pubmed.ncbi.nlm.nih.gov/31792259/T Landré, A Karaboué, Z S Buchwald...
https://pubmed.ncbi.nlm.nih.gov/38232612/Xiangji Ying, Kenneth E Freedland, Lynda H Powell...
https://pubmed.ncbi.nlm.nih.gov/40780848/Chen Wang, Qun Zeng, Zeynep Melis Gül...
https://pubmed.ncbi.nlm.nih.gov/38723627/Veronika Leichtfried, Raffaella Matteucci Gothe, Wilhelm Kantner-Rumplmair...
https://pubmed.ncbi.nlm.nih.gov/25159085/Mirjam Münch, Rolf Goldbach, Naomi Zumstein...
https://pubmed.ncbi.nlm.nih.gov/36193044/Craig Gouldthorpe, Jenny Power, Andrew Davies
https://pubmed.ncbi.nlm.nih.gov/37829342/Rohan Nagare, Mark S Rea, Barbara Plitnick...
https://pubmed.ncbi.nlm.nih.gov/30803301/Heiðdís B Valdimarsdottir, Mariana G Figueiro, William Holden...
https://pubmed.ncbi.nlm.nih.gov/30099857/Weill Medical College of Cornell University
Lead Sponsor
Circadian OS, Inc
Collaborating Sponsor